KR20180016972A - Cd137에 결합하는 항체 치료제 - Google Patents

Cd137에 결합하는 항체 치료제 Download PDF

Info

Publication number
KR20180016972A
KR20180016972A KR1020177026952A KR20177026952A KR20180016972A KR 20180016972 A KR20180016972 A KR 20180016972A KR 1020177026952 A KR1020177026952 A KR 1020177026952A KR 20177026952 A KR20177026952 A KR 20177026952A KR 20180016972 A KR20180016972 A KR 20180016972A
Authority
KR
South Korea
Prior art keywords
seq
ser
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177026952A
Other languages
English (en)
Korean (ko)
Inventor
존 딕슨 그레이
헤유 주
Original Assignee
소렌토 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소렌토 쎄라퓨틱스, 인코포레이티드 filed Critical 소렌토 쎄라퓨틱스, 인코포레이티드
Publication of KR20180016972A publication Critical patent/KR20180016972A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177026952A 2015-02-22 2016-02-22 Cd137에 결합하는 항체 치료제 Withdrawn KR20180016972A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119211P 2015-02-22 2015-02-22
US62/119,211 2015-02-22
PCT/US2016/018897 WO2016134358A1 (en) 2015-02-22 2016-02-22 Antibody therapeutics that bind cd137

Publications (1)

Publication Number Publication Date
KR20180016972A true KR20180016972A (ko) 2018-02-20

Family

ID=56690285

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026952A Withdrawn KR20180016972A (ko) 2015-02-22 2016-02-22 Cd137에 결합하는 항체 치료제

Country Status (12)

Country Link
US (4) US10259881B2 (https=)
EP (1) EP3258959A4 (https=)
JP (1) JP2018508509A (https=)
KR (1) KR20180016972A (https=)
CN (1) CN107921104A (https=)
AR (1) AR105313A1 (https=)
AU (1) AU2016219772A1 (https=)
CA (1) CA2977257A1 (https=)
IL (1) IL254088A0 (https=)
MX (1) MX2017010793A (https=)
TW (1) TW201632559A (https=)
WO (1) WO2016134358A1 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR20180016972A (ko) * 2015-02-22 2018-02-20 소렌토 쎄라퓨틱스, 인코포레이티드 Cd137에 결합하는 항체 치료제
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3544628A4 (en) * 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
CN112210010B (zh) * 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR20240017409A (ko) * 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
CA3071383C (en) * 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
EP3728316B1 (en) 2017-12-19 2025-02-26 invoX Pharma Limited Fc binding fragments comprising a pd-l1 antigen-binding site
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CN111902429A (zh) * 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
JP7059388B2 (ja) 2018-03-23 2022-04-25 イーライ リリー アンド カンパニー 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
MX2020010653A (es) * 2018-04-09 2020-10-28 Origincell Therapeutics Co Ltd Anticuerpo anti-muerte programada-ligando 1 y su uso.
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
BR112020026819A2 (pt) * 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
SG11202102335YA (en) 2018-09-12 2021-04-29 Eucure Beijing Biopharma Co Ltd Anti-tnfrsf9 antibodies and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
CN120098128A (zh) * 2019-01-02 2025-06-06 Qlsf生物治疗药物公司 Cd137激动剂抗体及其用途
WO2020180398A1 (en) * 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
CN120441704A (zh) 2019-06-26 2025-08-08 圆祥生技股份有限公司 T细胞活化抗体
JP7634001B2 (ja) * 2019-10-11 2025-02-20 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
EP4100439A4 (en) * 2020-02-05 2024-05-29 The Board Of Regents Of The University Of Texas System NOVEL LILRB2 ANTIBODIES AND USES THEREOF
CN115605228A (zh) * 2020-04-17 2023-01-13 苏州丁孚靶点生物技术有限公司（Cn） 一种特异性结合cd137的制剂及其用途
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
CN116194124A (zh) * 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
WO2023098785A1 (zh) * 2021-12-01 2023-06-08 上海君实生物医药科技股份有限公司 抗4-1bb抗体及其用途
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用
AU2024330458A1 (en) * 2023-09-01 2026-02-12 Amgen Inc. Molecules for treatment of cancer
WO2025189194A1 (en) * 2024-03-08 2025-09-12 Dana-Farber Cancer Institute, Inc. Antibodies against vegf and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00502B (me) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR20180016972A (ko) * 2015-02-22 2018-02-20 소렌토 쎄라퓨틱스, 인코포레이티드 Cd137에 결합하는 항체 치료제
EP3265486A4 (en) * 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
EP3827019A1 (en) * 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN120623346A (zh) * 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物

Also Published As

Publication number Publication date
US20160244528A1 (en) 2016-08-25
TW201632559A (zh) 2016-09-16
CA2977257A1 (en) 2016-08-25
JP2018508509A (ja) 2018-03-29
CN107921104A (zh) 2018-04-17
MX2017010793A (es) 2018-07-06
US20170226215A1 (en) 2017-08-10
US11180568B2 (en) 2021-11-23
US20220025064A1 (en) 2022-01-27
WO2016134358A1 (en) 2016-08-25
AU2016219772A1 (en) 2017-09-21
EP3258959A4 (en) 2018-10-17
US10259881B2 (en) 2019-04-16
IL254088A0 (en) 2017-10-31
EP3258959A1 (en) 2017-12-27
US20190161554A1 (en) 2019-05-30
US10233251B2 (en) 2019-03-19
AR105313A1 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
US11180568B2 (en) Antibody therapeutics that bind CD137
JP7273101B2 (ja) Ｃｄ３８に結合する抗体治療剤
US10927171B2 (en) Antibody therapeutics that bind TIM3
KR102850868B1 (ko) Cd47에 결합하는 항체 치료제
KR20180006367A (ko) Ctla4에 결합하는 항체 치료제
CN108348601A (zh) 与lag3结合的抗体治疗剂
KR20160138309A (ko) Cd147에 결합하는 항체 치료제
HK40060959A (en) Antibody therapeutics that bind cd38
HK1253584B (zh) 与cd38结合的抗体治疗剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170922

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination